Bristol-Myers Squibb Company (BMY) · page 121 of 197
The slide highlights the long-term cash burn associated with the Celgene acquisition pipeline.
Activist deck · valuation_table · diagnose_problem · overcrowded density
Slide locked Sign in to view
Slide schematic 6/6
callout 1/1 legend 1/1 list 1/1 paragraph 1/1 table 1/1 title 1/1
Components 6
primary legend bullet paragraph data headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.